NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer.

Instability in the composition of gut bacterial communities (dysbiosis) has been linked to common human intestinal disorders, such as Crohn's disease and colorectal cancer. Here, we show that dysbiosis caused by Nod2 deficiency gives rise to a reversible, communicable risk of colitis and colitis-associated carcinogenesis in mice. Loss of either Nod2 or RIP2 resulted in a proinflammatory microenvironment that enhanced epithelial dysplasia following chemically induced injury. The condition could be improved by treatment with antibiotics or an anti-interleukin-6 receptor-neutralizing antibody. Genotype-dependent disease risk was communicable via maternally transmitted microbiota in both Nod2-deficient and WT hosts. Furthermore, reciprocal microbiota transplantation reduced disease risk in Nod2-deficient mice and led to long-term changes in intestinal microbial communities. Conversely, disease risk was enhanced in WT hosts that were recolonized with dysbiotic fecal microbiota from Nod2-deficient mice. Thus, we demonstrated that licensing of dysbiotic microbiota is a critical component of disease risk. Our results demonstrate that NOD2 has an unexpected role in shaping a protective assembly of gut bacterial communities and suggest that manipulation of dysbiosis is a potential therapeutic approach in the treatment of human intestinal disorders.

[1]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[2]  P. Rosenstiel,et al.  Nod2 is essential for temporal development of intestinal microbial communities , 2011, Gut.

[3]  B. Pulendran,et al.  Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17–producing T cell responses , 2007, Nature Immunology.

[4]  C. Manichanh,et al.  Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.

[5]  R. Kaul,et al.  Identification of an innate T helper type 17 response to intestinal bacterial pathogens , 2011, Nature Medicine.

[6]  B. Ryffel,et al.  Remote control of intestinal tumorigenesis by innate immunity. , 2010, Cancer research.

[7]  G. Church,et al.  Systematic determination of genetic network architecture , 1999, Nature Genetics.

[8]  Richard A. Flavell,et al.  Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal Tract , 2005, Science.

[9]  J. Hampe,et al.  Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection , 2006, Cellular microbiology.

[10]  S. Fisher,et al.  Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations , 2001, The Lancet.

[11]  Jeffrey N. Weiser,et al.  Recognition of Peptidoglycan from the Microbiota by Nod1 Enhances Systemic Innate Immunity , 2010, Nature Medicine.

[12]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[13]  Markus F Neurath,et al.  An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression , 2007, Nature Protocols.

[14]  M. Chamaillard,et al.  Nods, Nalps and Naip: intracellular regulators of bacterial‐induced inflammation , 2003, Cellular microbiology.

[15]  Richard A. Flavell,et al.  NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis , 2011, Cell.

[16]  A. Macpherson,et al.  Adaptation of Solitary Intestinal Lymphoid Tissue in Response to Microbiota and Chemokine Receptor CCR7 Signaling1 , 2006, The Journal of Immunology.

[17]  F. Bäckhed,et al.  Host-Bacterial Mutualism in the Human Intestine , 2005, Science.

[18]  R. Knight,et al.  Evolution of Mammals and Their Gut Microbes , 2008, Science.

[19]  R Balfour Sartor,et al.  Microbial influences in inflammatory bowel diseases. , 2008, Gastroenterology.

[20]  G. Núñez,et al.  The cytosolic sensors Nod1 and Nod2 are critical for bacterial recognition and host defense after exposure to Toll-like receptor ligands. , 2008, Immunity.

[21]  K. Doi,et al.  Histochemical, lectin-histochemical and morphometrical characteristics of intestinal goblet cells of germfree and conventional mice. , 1996, Experimental animals.

[22]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[23]  J. Gordon,et al.  Homeostasis and Inflammation in the Intestine , 2010, Cell.

[24]  Judy H. Cho,et al.  [Letters to Nature] , 1975, Nature.

[25]  Tomohiro Watanabe,et al.  Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. , 2008, The Journal of clinical investigation.

[26]  M. Chamaillard,et al.  Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury , 2011, Proceedings of the National Academy of Sciences.

[27]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[28]  R. Gearry,et al.  Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. , 2006, Cancer research.

[29]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[30]  M. Neurath,et al.  STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing , 2009, The Journal of experimental medicine.

[31]  T. Yamamoto,et al.  Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse , 2004, Alimentary pharmacology & therapeutics.

[32]  T. Kishimoto,et al.  IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis1 , 2000, The Journal of Immunology.

[33]  S. Spechler,et al.  Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer , 2009, Nature Reviews Gastroenterology &Hepatology.

[34]  Tomas Hrncir,et al.  Nod2 is required for the regulation of commensal microbiota in the intestine , 2009, Proceedings of the National Academy of Sciences.

[35]  M. Gazouli,et al.  Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population , 2005, International journal of cancer.

[36]  U Wahnschaffe,et al.  Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease , 2006, Gut.

[37]  Wendy S. Garrett,et al.  Communicable Ulcerative Colitis Induced by T-bet Deficiency in the Innate Immune System , 2007, Cell.

[38]  M. Neurath,et al.  Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue , 2007, Nature Protocols.

[39]  F. Shanahan,et al.  Culture-Independent Analyses of Temporal Variation of the Dominant Fecal Microbiota and Targeted Bacterial Subgroups in Crohn's Disease , 2006, Journal of Clinical Microbiology.

[40]  Rodney J Scott,et al.  The NOD2 3020insC Mutation and the Risk of Colorectal Cancer , 2004, Cancer Research.

[41]  Michael Krawczak,et al.  Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer , 2009, BMC gastroenterology.

[42]  P. Allen,et al.  Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. , 2011, Cell host & microbe.

[43]  P. Vandamme,et al.  Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives , 2011, Gut.

[44]  P. Bork,et al.  Enterotypes of the human gut microbiome , 2011, Nature.

[45]  N. Pace,et al.  Disease phenotype and genotype are associated with shifts in intestinal‐associated microbiota in inflammatory bowel diseases , 2011, Inflammatory bowel diseases.

[46]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[47]  P. Rosenstiel,et al.  ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation , 2012, Nature.

[48]  K. Honda,et al.  Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species , 2011, Science.

[49]  S. Hunt,et al.  Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post‐hepatectomy in mice , 2006, Hepatology.

[50]  Marion Leclerc,et al.  Altered gut microbiota composition in immune-impaired Nod2−/− mice , 2011, Gut.

[51]  Andre Franke,et al.  Microbial Exposure During Early Life Has Persistent Effects on Natural Killer T Cell Function , 2012, Science.

[52]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[53]  Fiona Powrie,et al.  An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer , 2010, The Journal of experimental medicine.